887.8000 17.55 (2.02%)
NSE Jul 11, 2025 15:31 PM
Volume: 428.1K
 

887.80
2.02%
Axis Direct
Strides reported Q4'17 EBITDA of Rs 1.56bn, 28% below our expectations, hit by challenging environment across key markets. EBITDA including other income was Rs 2.1 bn, which is ~95% of H2'17 EBITDA guidance.
Promoters unpledged 2.27% of shares in last quarter. Total pledge stands at 51.98% of promoter holdings
More from Strides Pharma Science Ltd.
Recommended